HERMES

HERMES Trial

Sponsor: NovoNordisk

The HERMES-trial is a double-blind, randomized, placebo-controlled clinical trial investigating Ziltivekimab (IL-6 inhibitor vs. Placebo) in patients with heart failure with midrange- and heart failure with a preserved ejection fraction with inflammation.

Studyteam:

  • SI: G.H.D. Voordes, A. Tubben.
  • Research nurses: Z.F.M. Wiering, M.F. Couperus, C. Wijnbergen
  • Project coordinators: A. Branderhorst

 

 

People involved

Principal investigator

Adriaan Voors

Cardiologist